Physician profile
Anthony G Wayne
NPI 1407874670
$6,520.47
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $755 · 2021: $738 · 2022: $1,509 · 2023: $1,521 · 2024: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,739.04 | 2019-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $1,412.45 | 2022-2024 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $638.76 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $470.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $386.75 | 2019-2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Cranial Technologies, INC | $317.40 | 2019-2024 | Doc Band |
| Adlon Therapeutics L.P. | $284.58 | 2019-2021 | |
| Glaxosmithkline, LLC. | $172.38 | 2019-2024 | Nucala |
| Vertical Pharmaceuticals, LLC | $159.18 | 2019-2024 | Relexxii, Methylphenidate Hydrochloride |
| Rhodes Pharmaceuticals L.P. | $117.97 | 2019 | |
| Pfizer INC. | $109.31 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $104.77 | 2021-2024 | Qelbree, Qelbree |
| Bioxcel Therapeutics, INC. | $104.34 | 2024 | Igalmi |
| Sobi, INC | $65.03 | 2020-2023 | |
| Cumberland Pharmaceuticals, INC. | $62.25 | 2023 | Kristalose |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $60.38 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $56.77 | 2024 | |
| Shire North American Group INC | $53.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $52.33 | 2023-2024 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $49.09 | 2019 | |
| Nestle Healthcare Nutrition INC. | $32.79 | 2021-2022 | |
| Genentech USA, INC. | $31.85 | 2020 | |
| Arbor Pharmaceuticals, INC. | $27.03 | 2019 | |
| Phadia US INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Wayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.